Ownership Submission
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Narasimhan Mani
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-07-25
|
3. Issuer Name and Ticker or Trading Symbol
TRxADE HEALTH, INC [MEDS]
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O TRXADE HEALTH, INC. , 6308 BENJAMIN RD, SUITE 708
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
__X__ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
|
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Narasimhan Mani
C/O TRXADE HEALTH, INC.
6308 BENJAMIN RD, SUITE 708
TAMPA, FL33634
|
X
|
|
|
|
Signatures
|
/s/ Louis Kern, as attorney-in-fact for Narasimhan Mani
|
2024-08-05
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
These securities of TRxADE HEALTH, INC. (the "Issuer") were issued to Narasimhan Mani in connection with the closing of the acquisition of Scienture, Inc. ("Scienture") by the Issuer on July 25, 2024 (the "Merger") pursuant to an Agreement and Plan of Merger entered into by the Issuer, certain subsidiaries of the Issuer, and Scienture (the "Merger Agreement").
|
|
(2)
|
These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Preferred Stock"), have no expiration date. On the 20th calendar day following the mailing of an information statement on Schedule 14C that the Issuer is filing with the Securities and Exchange Commission and mailing to its stockholders in connection with the closing of the Merger, these shares of Preferred Stock will automatically convert on a 1-for-1 basis into fully paid and nonassessable shares of the Issuer's common stock, par value $0.00001.
|
|
(3)
|
These shares of Preferred Stock are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Mr. Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Mr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
